From: Antimicrobial use for selected diseases in cats in Switzerland
Parameter | University hospitals | Private practices | p-value | |
---|---|---|---|---|
Total number of cases | n = 130 | n = 203 | ||
Urine analysis performed | Yesb | 119 (92%) | 55 (27%) | <0.001 |
Sediment analysis | Yesb | 93 (72%) | 50 (25%) | <0.001 |
Bacterial culture | Yesb | 113 (87%) | 20 (10%) | <0.001 |
Confirmed bacterial etiologyc | Yesb | 45 (35%) | 16 (8%) | <0.001 |
Hospitalization | Yesb | 90 (69%) | 30 (15%) | <0.001 |
Pre-treated with antibiotics | Yesb | 23 (18%) | 4 (2%) | <0.001 |
Unknown | 5 (4%) | 3 (2%) | ||
Antibiotic therapy | Yesb | 85 (65%) | 115 (57%) | n.s.d |
Antibiotic classes | Potentiated aminopenicillins | 71 (84%) | 50 (57%) | <0.001 |
Third generation cephalosporins | 7 (8%) | 44 (38%) | <0.001 | |
Fluoroquinolones | 5 (6%) | 20 (17%) | 0.017 | |
Aminopenicillins | 1 (1%) | 22 (19%) | <0.001 | |
First generation cephalosporins | 5 (6%) | 1 (1%) | n.s.d | |
Amphenicols | 1 (1%) | 0 (0%) | n.s.d | |
Tetracyclines | 1 (1%) | 0 (0%) | n.s.d | |
Combination or serial therapye | Yesb | 6 (7%) | 20 (17%) | n.s.d |
Critically important antibiotice | Yesb | 12 (14%) | 62 (54%) | <0.001 |
Duration of therapy (days) | Median (range) | 13 (1 ̶56) | 9 (1 ̶42) | 0.012 |
Justification scoree | 1 | 57 (44%) | 24 (12%) | <0.001 |
2 | 1 (1%) | 0 (0%) | n.s.d | |
3 | 22 (17%) | 9 (4%) | <0.001 | |
4 | 39 (30%) | 11 (6%) | <0.001 | |
Judgement not possible | 11 (8%) | 159 (78%) | <0.001 |